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Background: It is important for Dental Professionals to consider the evidence for the effectiveness of the preventive
strategies used to maintain good oral health and reduce the risk of caries in their patients. Whilst many of the traditional
preventive activities, including the recommendation and use of fluoride products and the placement of fissure sealants
have a wealth of clinical evidence to support their use, some of the newer preventive agents have a more
limited evidence base. In order to investigate the level of scientific support behind one such technology, a
systematic literature review was carried out to assess the effectiveness of Tooth Mousse® (MI Paste®) and
Tooth Mousse Plus® (MI Paste Plus®) in the prevention and treatment of early dental caries.
Methods: A broad search strategy using Medline via OvidSP and EMBASE was performed in order to capture all
published studies to related Casein Phosphopeptide-Amorphous Calcium Phosphate. In addition to the above searches
the terms “CPP ACP” and “casein phosphopeptide amorphous calcium phosphate” were searched using PREMEDLINE
and the Cochrane Central Register of Controlled Trials. Inclusion criteria were clinical trials of participants of any
age, comparing the use of Tooth Mousse® (MI Paste®) or Tooth Mousse Plus® (MI Paste Plus®) to a routine
oral care regimen and reporting recognised clinical outcome measures for early caries lesions. Only research
studies in English were selected.
Results: 7576 articles were identified, but the majority were duplicates. Once these were removed 172 articles
were inspected and the focus on ‘CPP-ACP formulations of Tooth Mousse® (MI Paste®) and Tooth Mousse
Plus® (MI Paste Plus®) resulted in 29 articles being selected, and of these 12 studies met the inclusion criteria
and were considered acceptable for the systematic review.
Discussion: The overall findings of this review did not show any significant benefits of using Tooth Mousse®
(MI Paste®) products over brushing with a fluoride toothpaste for the prevention of early dental caries. With
regard to the regression of white spot lesions in orthodontic patients there is a tendency towards a benefit
for the use of Tooth Mousse® (MI Paste®) but the quality of evidence is limited. There is a lack of evidence to
support the use of Tooth Mousse Plus® (MI Paste Plus®) over Tooth Mousse® (MI Paste®) at this time.
Conclusion: This review suggests that further well-designed randomized controlled trials are required prior to
the widespread recommendation of Tooth Mousse® products for the prevention and treatment of early dental
caries in the general population.
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Forty years ago dental caries was a major health problem
for most children and adults living in developed coun-
tries and the dental profession was unable to cope with
the demand for clinical care [1]. Since then the preva-
lence and severity of dental caries has declined. For
example the mean DMFT for 12 year olds in Australia
dropped from 4.8 in 1977 to 1.1 in 1993 [2] and in the
United Kingdom from 3.1 in 1973 to 0.8 in 2003 [3].
The change in caries prevalence has been accompanied
by an alteration in the distribution of lesions, with pit
and fissure caries levels increasing [4]. Despite the gen-
eral improvements in oral health, caries continues to be
a challenge for the dental team, particularly for those
clinicians working in low income and socially disadvan-
taged areas where the prevalence of caries is still a public
health issue. Another change that has had an impact on
clinical practice is the increased prevalence of new cari-
ous lesions in adults, reaching a level as high as that
seen in children [5]. Therefore, the profession has to
plan treatment and preventive care pathways based on
the understanding that dental caries is no longer a rap-
idly developing problem in childhood, but a slowly pro-
gressing disease of adulthood.
The general decline in dental caries that has occurred
may have led to some complacency amongst the dental
team when considering the impact preventive care can
have on patients. This conundrum is demonstrated in a
study which found that 25 % of children initially caries
free developed caries over the following three years and
those with one carious lesion were five times more likely
to develop more lesions when compared with those free
of the disease [6]. Therefore professionals who only pro-
vide preventive advice to those with dental caries will be
doing a disservice to many patients.
Given that oral health care advice is a key part of the
dental service for patients it is important to consider the
evidence for the effectiveness of our preventive activities.
We want to be confident we can maintain good oral
health and reduce the risk of caries.
There are four potential preventive strategies which
can be used by the dental team, namely
 Regular disturbance of the plaque biofilm by
brushing twice a day with a fluoride toothpaste [7].
Other fluoride agents may also be added if the caries
risk warrants their use [8–11].
 Reduction in the frequency of consumption of
refined carbohydrate [12].
 Placement of pit and fissure sealants, to address the
increase in occlusal caries [13].
 Regular monitoring of early carious lesions to check
for progression and determine if fluoride products
are being used appropriately. Reinforcement oflifestyle changes such as controlling the frequency of
sugar consumption and brushing with a fluoride
toothpaste twice a day [14].
It is clear that there is a wealth of scientific evidence
supporting these preventive strategies, especially the
use of fluorides. However research scientists have also
investigated other agents which could be of value in
helping the dental team and their patients to control
dental caries. Ones which have achieved great popu-
larity are Tooth Mousse® (MI Paste®) and Tooth
Mousse Plus® (MI Paste Plus®) containing the active
ingredient casein phosphopeptide – amorphous cal-
cium phosphate (CPP-ACP) and are marketed by the
GC Corporation.
These products are based on the pioneering work of
Professor Eric Reynolds and his team at the University
of Melbourne Dental School [15], who developed
Recaldent®(CPP-ACP technology). Tooth Mousse®
(MI Paste®) contains 10 % of the Recaldent® molecule by
weight. Calcium phosphopeptide (CPP) is a milk derived
protein able to bind calcium and phosphate ions, and
stabilise them as amorphous calcium phosphate (ACP).
CPP-ACP adheres intra-orally to plaque pellicle, hydroxy-
apatite as well as soft tissues. It supplies bioavailable
calcium and phosphate into saliva and plaque fluid
enabling it to drive remineralisation [16]. In vitro
studies demonstrate that when placed on the surface
of a tooth, CPP-ACP interacts with hydrogen ions
and can diffuse into enamel where it produces sub-
surface mineral gains [17].
Tooth Mousse Plus® (MI Paste Plus®) contains 900
parts per million fluoride in a molar ratio with the cal-
cium and phosphate of 5 calcium, 3 phosphate and 1
fluoride which is reported by Reynolds and co-workers
as the ideal ratio for building fluorapatite [18, 19].
The development of the GC products Tooth Mousse®
(MI Paste®) and Tooth Mousse Plus® (MI Paste Plus®) is
to be applauded as scientific innovation is critical in the
quest to improve the oral health of patients. However
when the dental team use and recommend products for
patient care there must be sound scientific evidence to
support their treatment planning decisions and advice.
CPP-ACP in the form of Tooth Mousse® (MI Paste®) and
Tooth Mousse Plus® (MI Paste Plus®) are widely recom-
mended for the prevention of early dental caries. The
manufacturer instructions recommend Tooth Mousse®
(MI Paste®) for patients of any age except those with
milk protein allergies but limits the indication of Tooth
Mousse Plus® (MI Paste Plus®) to patients over six years
of age because of the fluoride content. These products
are much more expensive to use than fluoride products,
so it is important to examine the evidence supporting
their general usage. To this end a systematic review on
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tion and treatment has been undertaken, in order to de-
termine whether their efficacy warrants use in general
dental practice.
The aim of the systematic review is to answer the
question. “Is there sufficient clinical evidence available
to support the use of Tooth Mousse® (MI Paste®) and
Tooth Mousse Plus® (MI Paste Plus®) over a routine oral
care regimen for the prevention and treatment of early
dental caries?”Methods
A broad search strategy using Medline via OvidSP and
EMBASE was performed in order to capture all published
studies to related Casein Phosphopeptide-Amorphous
Calcium Phosphate (See Additional file 1). In addition to
the above searches the terms “CPP ACP” and “casein
phosphopeptide amorphous calcium phosphate” were
searched using PREMEDLINE and the Cochrane Central
Register of Controlled Trials. From these searches – one
record from PREMEDLINE was identified as relevant to
this review, whilst the Cochrane Database of Systematic
Reviews identified a protocol for a systematic review en-
titled “Non fluoride topical remineralising agents con-
taining calcium and/or phosphate for controlling dental
caries [20]. This review by the Cochrane collaboration
aims to evaluate non-fluoride topical remineralising
agents containing any formulation of calcium and/or
phosphate at any concentration and in any topically-
applied delivery vehicle and as such has a broader scope
than the focus of this review. The inclusion and exclu-
sion criteria used to filter the identified studies can be
found in Table 1.
The Cochrane Collaboration’s tool for assessing risk of
bias was utilized in the analysis [21]. The papers in-
cluded in the final review were assessed independently
by both authors (SR and AB) for risk of bias.Table 1 Inclusion and Exclusion criteria
Inclusion criteria
Participants: People of any age or gender at risk of dental caries.
Interventions: The use of Tooth Mousse® (MI Paste®) or Tooth
Mousse Plus® (MI Paste Plus®) in accordance with the manufacturer’s
instructions for the prevention or treatment of dental caries.
Comparisons: Tooth Mousse® (MI Paste®) or Tooth Mousse Plus®
(MI Paste Plus®) (Test) versus a routine oral care regimen for the
prevention of dental caries (Control) with or without comparisons
to additional preventive products.
Outcomes: Recognised clinical measures of early caries lesions or
enamel demineralisation including - enamel microhardness,
DIAGNOdent readings, QLF measurements, clinical caries
scoring and visual inspection of photographic images.
Study Design: Clinical trialsResults
A broad search of the literature was carried out in
December 2013 that identified 7576 articles of which the
majority were duplicates. Once these duplicates were
removed and the remainder limited to those where CPP-
ACP was the primary focus and published in English,
172 articles were identified for closer inspection. The
PREMEDLINE search identified one additional paper.
Of the 173 articles, the inclusion and exclusion criteria
in Table 1 were applied which led to 28 articles being
excluded immediately as they were review articles, case
reports or letters to the editor.
All of the 145 articles remaining were studied by title
and abstract as an initial filter. As the current systematic
review is focussed entirely on the CPP-ACP formula-
tions of Tooth Mousse® (MI Paste®) and Tooth Mousse
Plus® (MI Paste Plus®) – all studies employing any other
formulations of CPP-ACP including solutions, chewing
gum and dentifrice were excluded. This filter decreased
the number of articles to 29. These 29 articles were stud-
ied in full text, nine of which were excluded as they were
either in vitro studies or in situ studies utilising bovine en-
amel, giving 20 studies dating from 2007 to 2013 for final
review (Fig. 1). Eight of the twenty studies were excluded
– the titles and reasons for exclusion are summarised in
Table 2. Andersson et al. [22] did not use Tooth Mousse®
(MI Paste®) or Tooth Mousse Plus® (MI Paste Plus®) but
instead utilised a proprietary CPP–ACP dental crème
which is either no longer readily available or has been dis-
continued. Robertson et al. [23] delivered the MI Paste
Plus® in preformed trays, which does not follow the manu-
facturer’s directions for use. The remaining six [24–29]
studies were found on closer examination to have used out-
come measures not recognised as clinical care measures or
employed artificially demineralised tooth substance in an
‘in situ’ model which were exclusion criteria (See Table 1).
Both authors (SR and AB) reviewed the final 20 studies in-
dependently and reached consensus on which papers wereExclusion criteria
Reviews, case reports, abstracts, letters to editors, editorials,
commentaries, in vitro and in situ studies utilising bovine or
human enamel were excluded.
Non-english language studies were excluded.
Studies utilising an artificial caries model or enamel demineralization
model were excluded.
Interventions: Only Tooth Mousse® (MI Paste®) or Tooth Mousse Plus®
(MI Paste Plus®) formulations were considered. No other formulations
of CPP-ACP such as gum, lozenges, solutions, mouthrinses, toothpastes
or varnishes were considered.
Studies in which Tooth Mousse® (MI Paste®) or Tooth Mousse Plus®
(MI Paste Plus®) was not used in accordance with the manufacturer’s
directions for use were excluded.
Records identified through Medline 


























Additional records identified 
through PREMEDLINE
(n = 1)





(See Table 1 for criteria)
(n = 116)




(See Tables 1 and 2) 
(n = 17)
Studies included in 
qualitative analysis
(n = 12)
Fig. 1 Flowchart of systematic review process
Table 2 Studies excluded from the final review, with reasons for exclusion
Author Title Reason for exclusion
Andersson et al. [22] 2007 Effect of a dental cream containing amorphous calcium
phosphate complexes on white spot lesion regression
assessed by laser fluorescence.
Product used - a CPP-ACP dental crème which is difficult
to obtain or no longer available commercially.
Robertson et al. [23] 2011 MI Paste Plus® to prevent demineralisation in orthodontic
patients. A prospective randomised controlled trial.
Product delivery – did not follow the recommended usage
instructions for the product.
Participants wore customised intra-oral trays containing MI
Paste Plus® for a minimum of 3–5 mins per day.
Kitasako et al. [24] 2010 The clinical application of surface pH measurements to
longitudinally assess white spot enamel lesions.
Outcome measure - surface pH of enamel.
Marchisio et al. [25] 2010 Salivary pH level and bacterial plaque evaluation in
orthodontic patients treated with Recaldent® products.
Outcome measure - salivary and plaque pH.
Thepyou et al. [26] 2013 Casein phophopeptide-amorphous calcium phosphate
and glass ionomer show distinct effects in the
remineralization of proximal artificial caries
lesion in situ.
Test specimens - artificial caries lesions.
Caruana et al. [27] 2009 The effect of casein and calcium containing paste
on plaque pH following a subsequent carbohydrate
challenge.
Outcome measure - plaque pH.
Ferrazzano et al. [28] 2011 In vivo remineralising effect of GC Tooth Mousse®
on early dental enamel lesion: SEM analysis.
Test specimens – artificially demineralised enamel.
Baroni et al. [29] 2014 A SEM and non-contact surface white light profilometry
in vivo study of the effect of a crème containing CPP-ACP
and fluoride on young etched enamel.
Outcome measure - incisor surface morphology using
scanning electron microscope and white light profilometry
following etching with 37 % phosphoric acid.
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Title Fluoride Exposure Study design Study population Assessment Results
Uysal et al. [30]
2010
Effects of different topical agents on
enamel demineralization around
orthodontic brackets: and in vivo an
in vitro studya
Unspecified water fluoridation.
All groups used non-fluoridated
toothpaste.
Single-blind randomized clinical







In vivo results showed
no statistical difference
between the two topical
agents. Both topical agents
showed statistically significant
difference from the control
group after 60 days.
Topical agents – Tooth Mousse®,
Fluoridin N5 5 % (22,600 ppm)
sodium fluoride topical gel and
control group. Application of Tooth
Mousse® or Fluoridin N% gel carried
out on teeth with orthodontic
brackets scheduled for extraction
after 60 days. No application on
patients in the control group.
Sitthisettapong
et al. [31] 2012
Effect of CPP-ACP paste on dental
caries in primary teeth: A
randomized trial
Non-fluoridated water. Fluoride
toothpaste (1000 ppm) used by
both groups.
Double-blind randomized placebo-
controlled clinical trial on the
prevention of caries in high caries
risk pre-school children. Topical
agents – Tooth Mousse® or placebo
paste.
296 pre-school children








No significant difference was
observed between Tooth
Mousse® group and placebo
group after 1 year





A randomized controlled clinical
trial comparing a remineralizing
paste with an anti-bacterial gel
to prevent early childhood caries
Unspecified water fluoridation.
Fluoride toothpaste (400 ppm)
used by all groups.
Randomized controlled trial
comparing Tooth Mousse®,
chlorhexidine gel and 0.304 %
(400 ppm) fluoride toothpaste for
reducing mutans streptococci
colonization and preventing early
childhood caries.






No significant difference in
incidence between the three
groups after 24 months.
Tooth Mousse® and chlorhexidine
gel were applied by child’s mother


























A double-blind randomized clinical trial
to test whether more white spot lesions
would regress in participants using
Tooth Mousse® than a placebo paste.
Patients applied Tooth Mousse® or
placebo paste twice daily following



















with severity codes 2 or




the placebo group at
12 weeks.




given at each assessment
visit to both groups.
Altenburger










A single-blind randomized clinical study
to test the daily application of Tooth
Mousse® to remineralize initially
demineralized enamel fissures com
pared to a control group. Patients in test
group applied Tooth Mousse® once daily
onto the occlusal surface of teeth.
32 subjects aged










Ekstrand et al. [42]




the test and control
groups after 2 and



















Unfluoridated water. A double-blind randomized clinical trial
to investigate the effects of Tooth
Mousse Plus® on dental plaque and on
the remineralization of enamel white
















depth was observed in
both groups. No
significant difference
was found between the






Patients applied Tooth Mousse Plus® or












A randomized single-blind clinical study
to investigate the effect of daily
applications of Tooth Mousse® on white
















regression of white spot
lesions measured by
visual inspection and





groups after 4 weeks.
Fluoride toothpaste
(1100 ppm) used once
daily in the test group
and twice daily in the
control group.
Patients in the test group applied Tooth
Mousse® once daily in the evening and
brushed with fluoride toothpaste in the
morning. Patients in the control group
































A single-blind clinical study to evaluate
the remineralizing effect of Tooth
Mousse® versus twice-daily brushing
with fluoride toothpaste on enamel
decalcification in orthodontics.















reductions in the EDI of
the Tooth Mousse®
group were found. No
statistically significant
reduction of EDI was
reported in the fluoride
toothpaste group
during the 6 month
study.
Patients in the test group applied Tooth
Mousse® once daily following evening
toothbrushing with non-fluoride
toothpaste. Patients in the control group









A prospective clinical controlled study to
determine the effectiveness of 0.025 %
(100 ppm) sodium fluoride mouthrinse,
Tooth Mousse® and the microabrasion
technique in reducing white spot lesions
compared with a control group.
Randomization of test and control
groups and blinding was not reported.
Patients in the Tooth Mousse® group
applied the crème twice daily after
toothbrushing with fluoride toothpaste.
Patients in the mouthrinse group rinsed
for 30 s twice daily after brushing with
fluoride toothpaste. In the microabrasion
group the procedure was performed
with a 18 % hydrochloric acid/pumice
mixture and was repeated four or five
times. Patients in the control group











reductions in the extent
of white spot lesions




success rates for the
postorthodontic
remineralization over a

















combination of 10 %









practices (use of fluoride
toothpaste was
unspecified).
A randomzed single-blind clinical study
to evaluate the efficacy of Tooth
Mousse®, Tooth Mousse Plus® compared
to 0.5 % fluoride mouthrinse for the
remineralisation of occlusal white spot
lesions. Patients in the Tooth Mousse®
and Tooth Mousse Plus® groups applied
the respective crèmes twice daily
following toothbrushing. Patients in the








Ekstrand et al. [42]
All 3 groups showed
highly significant
remineralising potential



































A randomized clinical study to evaluate
the remineralizing effect of Tooth
Mousse® on white spot lesions
compared with a control group. Blinding
of the examiner was not reported.
Patients in the Tooth Mousse® group
applied the crème twice daily after
toothbrushing. Patients in the control










There was a statistically
significant increase in
DIAGNOdent readings
in the control group
from baseline after




in the test group from














A randomized single-blind parallel group
trial comparing the effectiveness of daily
application of MI Paste Plus® for 8 weeks
with a single application of 5 % sodium
fluoride varnish to a control group in
improving the appearance of white spot
















in the test groups
compared to the
control group at the
end of the 8 week
study by any of the
examining panels.
Patients in the MI Paste Plus® group
applied the crème twice daily. Patients
in the fluoride varnish group received a
single application of varnish at the start
of the study. Patients in the control
group followed routine oral hygiene
at home.
aOnly the in vivo study was considered
bOnly the QLF results were considered
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this systematic review, three studies reported on prevention
[30–32] (Table 3) and nine reported on the treatment or re-
gression of caries [33–41] (Table 4).
Two of the three prevention studies were double-blind
randomized controlled trials in populations of pre-
school children [31, 32]. These studies found no signifi-
cant benefits in the use of Tooth Mousse® (MI Paste®)
over standard brushing with either 1000 ppm [31] or
400 ppm [32] fluoride toothpaste. The authors con-
cluded that there was insufficient evidence to justify the
daily use of Tooth Mousse® (MI Paste®) to control dental
caries in these populations. The other prevention study
published by Uysal et al. [30] was the in vivo study com-
paring the use of Tooth Mousse® or a 5 % sodium fluor-
ide gel with a control group to prevent white spot
lesions. The results of the in vitro study described in this
article were not considered or included in this system-
atic review. In the in vivo study, patients used a non-
fluoride toothpaste and did not receive any oral hygiene
instruction. This study showed a statistically significant
difference in the enamel microhardness of premolar
teeth extracted after the 60 day test period in both the
Tooth Mousse® and fluoride gel groups, compared to the
control group, but no significant difference between the
test groups.
Nine studies [33–41] reported on the treatment or
regression of dental caries (Table 4). In the majority of
studies fluoride toothpaste was used by participants in
all the study groups. However, one study [39] did not
specify whether fluoride toothpaste was used, a second
study did not fully specify the use of fluoride toothpaste
in all groups [38] and in another [37] a non-fluoride
toothpaste was used in the test group but fluoride tooth-
paste was used in the control group.
All except two [34, 39] of the nine studies reported on
the regression of white spot lesions in orthodontic pa-
tients. This body of evidence, containing seven clinical
studies [33, 35–38, 40, 41] of variable strength of evidence
utilised either visual scoring or fluorescence techniques
for the assessment of dental caries. Some were compared
with placebo pastes and others with different preventive
products and/or control groups. Of these seven studies,
four showed a significant advantage from the use of Tooth
Mousse® in the regression of white spot lesions in ortho-
dontic patients over 12 weeks to 6 months [33, 37, 38, 40].
The remaining three studies reported no significant
difference between the Tooth Mousse® (MI Paste®) or
Tooth Mousse Plus® (MI Paste Plus®) group and con-
trol/placebo group over periods of four weeks to
three months [35, 36, 41].
Altenburger et al. [34] reported the remineralization
of demineralized enamel fissures in 32 young adults
using Tooth Mousse® using both laser fluorescence andvisual classification. The Tooth Mousse® group showed
significant improvements in laser fluorescence but no
difference was noted by the visual scoring at 2 and
3-weeks when compared to the control group.
Krithikadatta et al. [39] carried out a pilot study on 45
adolescent dental students with occlusal white spot le-
sions, comparing Tooth Mousse® and Tooth Mousse
Plus® to a 0.5 % fluoride mouthrinse. All three groups
showed highly significant remineralising potential over
the 30 day test period, but Tooth Mousse® and Tooth
Mousse Plus® were significantly more effective than the
fluoride mouthrinse.
Of the twelve studies included in this systematic
review, three studies were direct comparisons of Tooth
Mousse® versus a control group [34, 36, 40] and two
studies versus a placebo crème [31, 33]. The remaining
six studies compared the efficacy of Tooth Mousse®
(MI Paste®) and/or Tooth Mousse Plus® (MI Paste
Plus®) to other products and techniques with or
without a control group - including fluoride tooth-
paste [37], fluoride mouthrinse [38, 39], fluoride gel
[30], fluoride varnish [41], chlorhexidine gel [32] and
microabrasion [38]. The studies by Beerens et al.
[35], Krithidkadatta et al. [39], and Huang et al. [41]
involved comparisons with Tooth Mousse Plus® (MI
Paste Plus®) - containing 900 ppm Fluoride, all other
studies utilised only the non-fluoride containing Tooth
Mousse® (MI Paste®).
With regard to safety, no serious side effects or adverse
events were reported in any of the studies included in the
final review. However, five studies [35, 37, 39–41] did not
report side effects or adverse events in their papers. One
study [33] recorded one participant with non-serious
gastro-intestinal symptoms that were possibly related to
the use of Tooth Mousse® and another [38] made the
statement “although CPP-ACP had side effects” but did
not make any reference to what the side effects were.
Figure 2 indicates that the prevention studies in-
cluded in our review were classified as having a low
risk of bias, although questions are raised on the
Uysal et al. [30] research on possible selection and
performance bias and Plonka et al. [32] has a ques-
tion mark over outcome assessment. The regression
studies do not show such good results (Fig. 3) with
over half having questionable scores for selection bias
and the majority having high risk of performance
bias.
The strength of evidence of the group of studies included
in this systematic review are further weakened by short ob-
servation periods (five studies with duration shorter than
3 months [30, 34, 36, 38, 41]), varying outcome measures
(clinical indices [31–34, 39, 40], enamel microhardness
[30], laser and light-induced fluorescence [34–36, 39, 40]
and visual scoring of photographs [36–38, 41]) and small
Fig. 2 Presentation of the risk of bias assessments for the prevention
studies included in the review
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prevention studies [30–32] and 542 participants for the
nine regression studies [33–41]).Fig. 3 Presentation of the risk of bias assessments for the regression
studies included in the reviewDiscussion
The initial literature search on CPP-ACP yielded a huge
number (7576) of publications, however a close scrutiny
of the results identified 172 articles that were worthy de-
tailed inspections. Ultimately, 20 articles were selected
but eight studies (Table 2) were excluded, giving just 12
papers to consider, three focusing on prevention and
nine on controlling dental caries.
If the research data for the prevention of dental caries
is assessed, two of the studies [31, 32] which were ran-
domised controlled trials (over 12 and 24 months re-
spectively), reported that Tooth Mousse® did not offer a
benefit in terms of a reduction in dental caries for young
children over brushing with a fluoride toothpaste. Whilst
the third prevention study [30] reported enamel demin-
eralisation (over a relatively short period of 60 days) in a
group of orthodontic patients and once again a fluoride
product performed just as well as Tooth Mousse®. There-
fore, it would be unwise to recommend Tooth Mousse®
(MI Paste®) for the prevention dental caries.One might also consider it somewhat unusual that the
bulk of the evidence on remineralisation studies comes
from orthodontic patients who are a very select group of
individuals undergoing specialist dental care and not
typical of the general population. However it would
be unwise to dismiss the results because of the narrow
specificity of the target group as it would reduce the
data set to two studies. If one considers the orthodontic
publications there is a some degree of evidence for the
benefits of regression of white spot lesions, with four
studies [33, 37, 38, 40] showing positive results and three
[35, 36, 41] showing no significant difference to the
control groups. When the three studies [35, 39, 41]
utilising Tooth Mouth Plus® (MI Paste Plus®) are
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with a direct comparison between Tooth Mousse® and
Tooth Mousse Plus®. The results of this study did not
show a significant difference between the non-fluoride
and fluoride-containing forms of the CPP-ACP crème
and the authors suggested that further studies would be
required to confirm these results.
There is a wide variation in the study designs, blinding,
protocols and outcome measures in this group of studies
making meta-analysis impossible. Clearly, more rando-
mised longer-term trials are required utilizing Tooth
Mousse® (MI Paste®) and Tooth Mousse Plus® (MI Paste
Plus®) in accordance with the manufacturer’s instructions
to clarify the benefits of use in orthodontic patients. In the
general population, those individuals at high risk of devel-
oping dental caries are commonly of low socio-economic
status and have less disposable income for oral care prod-
ucts. Whilst Tooth Mousse® (MI Paste®) has the advantage
of being fluoride-free, making it suitable for use in very
young children, the risk of development of fluorosis of the
permanent teeth from the excessive ingestion of fluoride
toothpaste is not a concern for children 6 years of age and
older. The two papers [31, 32] in this review that studied
the efficacy of Tooth Mousse® (MI Paste®) in children
under 6 years of age do not support its use over the twice-
daily use of either 1000 ppm [31] or 400 ppm [32] fluoride
toothpaste. As it is also much more expensive than fluoride
toothpaste the recommendation of this product in very
young children cannot be supported.
With regard to the benefits of Tooth Mousse® (MI
Paste®) or Tooth Mousse Plus® (MI Paste Plus®) in people
6 years of age and above, we certainly require more work
to support its general use for the prevention and treat-
ment of early caries apart from perhaps those patients
undergoing orthodontic care which is often the province
of more affluent individuals.
The risk of bias assessment raises important issues
with the regression studies, and clearly more robust and
well-executed randomised studies are required.
Conclusions
The findings of this systematic review suggest there is a
lack of evidence to support the use of Tooth Mousse®
(MI Paste®) over a routine preventive fluoride regimen for
the prevention of early dental caries. With regard to the
use of Tooth Mousse® (MI Paste®) and Tooth Mousse Plus®
(MI Paste Plus®) for the regression of white spot lesions
associated with orthodontic treatment there is a tendency
towards a benefit for their use but the quality of evidence
is limited. Furthermore, at this time there is a lack of
support for the use of fluoride-containing formulation -
Tooth Mousse Plus® (MI Paste Plus®) over Tooth Mousse®
(MI Paste®). New products require testing over time and
the lack of sufficient high level clinical evidence for theefficacy of these specific casein phosphopeptide amorphous
calcium phosphate-containing products remains a limita-
tion. Further well-designed randomized controlled trials
are required prior to the widespread recommendation of
Tooth Mousse® (MI Paste®) or Tooth Mousse Plus® (MI
Paste Plus®) for the prevention and treatment of early den-
tal caries in the general population.
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